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Oral Presentations S163\1% in mice given HSC), accompanied by a substantial increase of
host NK cells (median 14% vs\1%; 6.3 vs\0.4 x10^5 cells). Donor
CD4 TC in the BM expressed high levels of IFNg (30-50%), which
exceeded IFNg secretion in control groups (3-15%). Similar find-
ings of engraftment failure due to donor CD4 TC were noted
when mice were conditioned with total lymphoid irradiation (TLI:
17240 cGy): while recipients of HSC alone were mixed chimeras
in all lineages, those given HSC +TC failed to engraft with T and
B cells, had only marginal myeloid engraftment, but increased pro-
portions of host NK cells in the PB. We conclude that after non-
myeloablative conditioning transplantation of pure HSC can result
in superior immune reconstitution and donor chimerism as com-
pared to grafts supplemented with CD4 TC. These results are of
broad significance, as it is generally believed that TC augment donor
HSC engraftment. The way in which CD4 TC retard engraftment
appears to be by induction of inflammation within the BMmicroen-
vironment and activation of host lymphoid populations that mediate
resistance. IFNg, which is a known regulator of innate and acquired
immune responses, may be central in activating host CD4 TC,
enhancing NK cell mediated rejection of the graft and/or suppres-
sion of donor hematopoiesis.23
CCR5 EXPRESSION ON CIRCULATING BLOOD DC POST-ALLOGENEIC HE-
MOPOIETIC CELL TRANSPLANT IS HIGHLY PREDICTIVE FOR THE DEVEL-
OPMENT OF CLINICALLY SIGNIFICANT ACUTE GRAFT VERSUS HOST
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Introduction:Dendritic cells (DC) are central to the development
of acute graft-versus-host disease (GvHD) following allogeneic he-
matopoietic cell transplantation (alloHCT). Because DC migration
is tightly regulated by the interaction between chemokine receptors
on DC and their ligands, we investigated the relationship between
the severity of acute GvHD and the expression of the chemokine
receptors CCR5 and CCR7 on CD11c+ myeloid and CD11c- plas-
macytoid DC from the peripheral blood of 32 patients post al-
loHCT.
Methods: Peripheral blood was collected twice weekly up to day 100
post transplant. The expression of each chemokine receptor on
CD11c+ and CD11c- DC was calculated using multiparameter
flow cytometry. The percentage of CD11c+ DC expressing a given
receptor was added to the percentage of CD11c- DC expressing
the same receptor to give a maximum score that could vary from
0 to 200%.
Results: Eleven of 32 patients developed moderate to severe acute
GvHD (grade II-IV), the remaining 21 patients developed either
no GvHD or only grade I GvHD. The percentage of DC express-
ing either CCR5 or CCR7 was correlated with the development of
acute GvHD. CCR7 expression was detected in 13 of 32 patients
post-HCT with a median of 2.3% of DC positive (range 0 to
39%). CCR7 expression on DC showed no association with the se-
verity of acute GvHD (p5 1.0). In contrast, higher CCR5 expres-
sion was detected on DC in patients developing grade II-IV
GvHD (median 98.0%, SEM 9.1%) than in those with grade 0-I
GvHD (median 5.2%, SEM 5.1%) p\0.0001. All eleven patients
with grade II-IV GvHD expressed CCR5 at a level of .35% of
myeloid and plasmacytoid DC. Only two of 21 patients with grade
1 GvHD expressed CCR5 at the same level (66% and 94%). Most
importantly, the expression of CCR5 preceded the development of
moderate to severe GvHD in all patients by a median of 19 days
(range 2 to 47 days, SEM 4.3 days). Using a receiver operator
curve analysis, CCR5 expression above 35% demonstrated a sensi-
tivity of 100% and a specificity of 90.5% for predicting grade II-IV
GvHD.
Conclusion:Expression of CCR5 on circulatingDCpost allo-HCT
predicts for the development of moderate to severe GvHD, and de-
tection could allow earlier therapeutic intervention prior to the de-
velopment of clinical GVHD.24
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Using murine models of acute GVHD in which allogeneic bone
marrow cells are transplanted into lethally irradiated hosts, we and
others have shown that donorCD4+CD25+Foxp3+ regulatoryT cells
(Treg) are able to suppress GVHD induced by donor allogeneic con-
ventional T cells (Tcon). The potential clinical use of Treg is limited
by their low number. To overcome this problem, expansion of Treg
has been performed, however, there has not been a head-to-head
comparison of the function of expanded vs. fresh Treg. Highly puri-
fied CD4+CD25+Foxp3+ T cells (.98% purity) were expanded
using anti-CD3/CD28 dynabeads and 1000 U/ml IL-2. Treg cul-
tured for five days expanded up to 13 fold while maintaining high
Foxp3 expression levels (85-90%). The expanded Treg (eTreg)
were evaluated in an in vivo acute GVHD mouse model in direct
comparison with freshly isolatedTreg (fTreg) using a novel biolumi-
nescent imaging assay (BLI) that allowed for quantitative assessment
of Tcon proliferation in addition to traditional metrics of GVHD se-
verity. Expanded Treg were significantly more effective at suppress-
ing the early proliferation of Tcon than an equal number of fTreg
(P\0.0001). On day 6, mice that received Tcon and eTreg had
a mean BLI signal of 1.5106 photons/sec/mouse, four times lower
than the signal of mice receiving Tcon and fTreg (5.8106 photons/
sec/mouse). The difference in potency may be explained by the in-
creased number of eTreg compared to fTreg that were re-isolated
from peripheral lymph nodes (PLN) (40,600 total eTreg/PLN/
mouse vs. 5,200 total fTreg/PLN/mouse) at day 5, suggesting that
expanded Treg arrived and proliferated in PLN faster than the fresh
Treg. However, over time, the eTreg lose their protective capabil-
ities and, in order to suppress GVHD symptoms and improve sur-
vival, a greater number of eTreg were required compared to
fTreg. On day 37, the mean GVHD score for the Tcon alone group
was 8.66 0.74. Fresh Treg added at 1:1 ratio with Tcon decreased
GVHD score to 1.46 0.25 (p\ 0.0001). Ex-vivo expanded Treg
demonstrated a dose-dependent decrease in GVHD score, although
four times more eTreg were needed to obtain a similar reduction in
GVHD score (0.336 0.3, p5 0.0002). Although eTreg are less
potent at suppressing GVHD than fTreg, the greater numbers
achievable by short-term culture makes them viable option for treat-
ment ofGVHD, however, increased ratios of Treg:Tcon are likely to
be required.25
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Background:Graft failure (GF) is a serious and fatal complication
that can occur in up to 30% of Fanconi anemia (FA) patients sub-
mitted to hemaopoietic stem cell transplantation. (HSCT). The
goal of this study was the analysis of risks factors for GF in patients
with FA.
Patient andMethods Between January 1985 and July 2008, 203 pts
with FA were submitted to an HSCT and 168 were evaluable for en-
graftment .Thirty-one had graft failure (group A), while 140pts had
an adequate engraftment (group B). Pts in group A had a longer du-
ration of the disease when compared to pts in group B (40 versus 19
months – p5 0,004) and they were also more transfused (43 versus 8
– p\0,001). Stem cell source: Group A: Bone marrow (BM) 65%
and umbilical cord blood (UCB) 35%. Group B: 85% BM and
15%UCB.Unrelated donors (UD) were used in 68%of pts in group
A and 28% in group B (p\0,001); there were also less compatible
transplant in group A (57 versus 79%- p5 0,01). A de-escalation
dose of cyclophosphamide was used for the majority of pts receiving
a related HSCT while a fludarabine based regimen was used in pts
with UD. GVHD prophylaxis consisted of cyclosporine and metho-
trexate in the majority of pts.
